

ONLINE APPENDIX: PREVIOUS WHI PUBLICATIONS

WHI Hormone Therapy Trial Publications: References and Links to Abstracts

1. Prentice R, Rossouw JR, Johnson SR, Freedman LS, McTiernan A. The role of randomized controlled trials in assessing the benefits and risks of long-term hormone replacement therapy: Example of the Women's Health Initiative. *Menopause* 1996; 3:71-76.
http://journals.lww.com/menopausejournal/Fulltext/1996/03020/The_Role_of_Randomized_Controlled_Trials_in.3.aspx
2. Anderson G, Cummings S, Freedman LS, Furberg C, Henderson M, Johnson SR, Kuller L, Manson JE, Oberman A, Prentice RL, Rossouw JE for the Design Manuscript Writing Group. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. *Control Clin Trials* 1998; 19(1):61-109.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Control+Clin+Trials+1998%3B+19\(1\)%3A61-109](http://www.ncbi.nlm.nih.gov/pubmed/?term=Control+Clin+Trials+1998%3B+19(1)%3A61-109).
3. Shumaker SA, Reboussin BA, Espeland MA, Rapp SR, McBee WL, Dailey M, et al. The Women's Health Initiative Memory Study (WHIMS): A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. *Control Clin Trials* 1998; 19(6):604-621.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Control+Clin+Trials+1998%3B+19\(6\)%3A604-621](http://www.ncbi.nlm.nih.gov/pubmed/?term=Control+Clin+Trials+1998%3B+19(6)%3A604-621).
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002; 288(3):321-333.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2002%3B+288\(3\)%3A321-333](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2002%3B+288(3)%3A321-333)
5. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. *N Engl J Med* 2003; 349(6):523-534.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2003%3B+349\(6\)%3A523-534](http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2003%3B+349(6)%3A523-534)
6. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: Overview and baseline characteristics of participants. *Ann Epidemiol* 2003; 13(9 Suppl):S78-86.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Ann+Epidemiol+2003%3B+13\(9+Suppl\)%3AS78-86](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ann+Epidemiol+2003%3B+13(9+Suppl)%3AS78-86).
7. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. *N Engl J Med* 2003; 348(7):645-650.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2003%3B+348\(7\)%3A645-650](http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2003%3B+348(7)%3A645-650).
8. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. *JAMA* 2003; 289(20):2673-2684. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+289\(20\)%3A2673-2684](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+289(20)%3A2673-2684).
9. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. *JAMA* 2003; 290(13):1739-1748.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+290\(13\)%3A1739-1748](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+290(13)%3A1739-1748)
10. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D, WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: A randomized controlled trial. *JAMA* 2003; 289(20):2663-2672.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+289\(20\)%3A2663-2672](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+289(20)%3A2663-2672).
11. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health-related quality of life. *N Engl J Med* 2003; 348(19):1839-1854.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2003%3B+348\(19\)%3A1839-1854](http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2003%3B+348(19)%3A1839-1854)
12. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA* 2003; 290(13):1729-1738.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+290\(13\)%3A1729-1738](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+290(13)%3A1729-1738)

13. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. *JAMA* 2003; 289(24):3243-3253.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+289\(24\)%3A3243-3253](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+289(24)%3A3243-3253).
14. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JE, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA* 2003; 289(20):2651-2662.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+289\(20\)%3A2651-2662](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2003%3B+289(20)%3A2651-2662).
15. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA* 2004; 291(24):2947-2958.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2004%3B+291\(24\)%3A2947-2958](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2004%3B+291(24)%3A2947-2958)
16. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. *JAMA* 2004; 291(24):2959-2968.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2004%3B+291\(24\)%3A2959-2968](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2004%3B+291(24)%3A2959-2968)
17. Hsia J, Criqui MH, Rodabough RJ, Langer RD, Resnick HE, Phillips LS, et al. for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative. *Circulation* 2004;109(5):620-626. <http://www.ncbi.nlm.nih.gov/pubmed/14769684>
18. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004; 291(14):1701-1712. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2004%3B+291\(14\)%3A1701-1712](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2004%3B+291(14)%3A1701-1712).
19. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. *JAMA* 2004; 292(13):1573-1580.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2004%3B+292\(13\)%3A1573-1580](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2004%3B+292(13)%3A1573-1580)
20. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. *Diabetologia* 2004; 47(7):1175-1187.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Diabetologia+2004%3B+47\(7\)%3A1175-1187](http://www.ncbi.nlm.nih.gov/pubmed/?term=Diabetologia+2004%3B+47(7)%3A1175-1187)
21. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. *N Engl J Med* 2004; 350(10):991-1004.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2004%3B+350\(10\)%3A991-1004](http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2004%3B+350(10)%3A991-1004).
22. Manson JE, Bassuk S. The menopause transition and postmenopausal hormone therapy. In: Kasper DL et al, eds. *Harrison's principles of internal medicine*. 16th ed. New York: McGraw-Hill, 2004:2209-2213.
23. Waters DD, Gordon D, Rossouw JE, Cannon RO 3rd, Collins P, Herrington DM, et al. National Heart, Lung and Blood Institute; American College of Cardiology Foundation. Women's Ischemic Syndrome Evaluation: current status and future research directions: Report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002 : Section 4: lessons from hormone replacement trials. *Circulation* 2004; 109(6):e53-55. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Circulation+2004%3B+109\(6\)%3Ae53-55](http://www.ncbi.nlm.nih.gov/pubmed/?term=Circulation+2004%3B+109(6)%3Ae53-55).
24. Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women's Health Initiative Study of Cognitive Aging (WHISCA): A randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. *Clin Trials* 2004; 1(5):440-450.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Clin+Trials+2004%3B+1\(5\)%3A440-450](http://www.ncbi.nlm.nih.gov/pubmed/?term=Clin+Trials+2004%3B+1(5)%3A440-450).
25. Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, et al. for the Women's Health Initiative Investigators. Combined postmenopausal hormone therapy and cardiovascular disease: Toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. *Am J Epidemiol* 2005; 162(5):404-414.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Epidemiol+2005%3B+162\(5\)%3A404-414](http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Epidemiol+2005%3B+162(5)%3A404-414).

26. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. *JAMA* 2005; 293(3):330-339. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2005%3B+293\(3\)%3A330-339](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2005%3B+293(3)%3A330-339).
27. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. *Obstet Gynecol* 2005; 105(5 Pt 1):1063-1073. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Obstet+Gynecol+2005%3B+105\(5+Pt+1\)%3A1063-1073](http://www.ncbi.nlm.nih.gov/pubmed/?term=Obstet+Gynecol+2005%3B+105(5+Pt+1)%3A1063-1073).
28. Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S, et al. Symptom experience after discontinuing use of estrogen plus progestin. *JAMA* 2005; 294(2):183-193. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2005%3B+294\(2\)%3A183-193](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2005%3B+294(2)%3A183-193).
29. McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, et al. for the Women's Health Initiative Mammogram Density Study Investigators. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. *JNCI* 2005; 97(18):1366-1376. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2005%3B+97\(18\)%3A1366-1376](http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2005%3B+97(18)%3A1366-1376).
30. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. *JAMA* 2005; 293(8):935-948. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2005%3B+293\(8\)%3A935-948](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2005%3B+293(8)%3A935-948).
31. Brunner RL, Gass M, Aragaki A, Hays J, Granek I, Woods N, et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. *Arch Intern Med* 2005; 165(17):1976-1986. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2005%3B+165\(17\)%3A1976-1986](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2005%3B+165(17)%3A1976-1986)
32. Chen Z, Bassford T, Green SB, Cauley JA, Jackson RD, LaCroix AZ, Leboff M, Stefanick ML, Margolis KL. Postmenopausal hormone therapy and body composition--a substudy of the estrogen plus progestin trial of the Women's Health Initiative. *Am J Clin Nutr* 2005; 82(3):651-656. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Clin+Nutr+2005%3B+82\(3\)%3A651-656](http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Clin+Nutr+2005%3B+82(3)%3A651-656).
33. Cirillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. *Arthritis Rheum* 2006; 54(10):3194-3204. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Arthritis+Rheum+2006%3B+54\(10\)%3A3194-3204](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arthritis+Rheum+2006%3B+54(10)%3A3194-3204)
34. Hsia J, Manson JE, Kuller L, Pettinger M, Choe JH, Langer RD, et al. Impact of cyclooxygenase inhibitors in the Women's Health Initiative Hormone Trials: Secondary analysis of a randomized trial. *PLoS Clin Trials* 2006; 1(5):e26. [http://www.ncbi.nlm.nih.gov/pubmed/?term=PLoS+Clin+Trials+2006%3B+1\(5\)%3Ae26](http://www.ncbi.nlm.nih.gov/pubmed/?term=PLoS+Clin+Trials+2006%3B+1(5)%3Ae26).
35. Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, et al. for the Women's Health Initiative Investigators. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. *Am J Epidemiol.* 2006; 163(7):589-599. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Epidemiol.+2006%3B+163\(7\)%3A589-599](http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Epidemiol.+2006%3B+163(7)%3A589-599).
36. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. *Arch Intern Med* 2006; 166(7):772-780. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2006%3B+166\(7\)%3A772-780](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2006%3B+166(7)%3A772-780)
37. Hsia J, Criqui MH, Herrington DM, Manson JE, Wu L, Heckbert SR, et al. for the Women's Health Initiative Research Group. Conjugated equine estrogens and peripheral arterial disease risk: The Women's Health Initiative. *Am Heart J* 2006; 152(1):170-176. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+Heart+J+2006%3B+152\(1\)%3A170-176](http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+Heart+J+2006%3B+152(1)%3A170-176)
38. Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, Curb JD, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. *Maturitas* 2006; 55(2):103-115. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Maturitas+2006%3B+55\(2\)%3A103-115](http://www.ncbi.nlm.nih.gov/pubmed/?term=Maturitas+2006%3B+55(2)%3A103-115)
39. Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, et al. for the Women's Health Initiative Study of Cognitive Aging Investigators. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. *J Clin Endocrinol Metab* 2006; 91(5):1802-1810. [http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Endocrinol+Metab+2006%3B+91\(5\)%3A1802-1810](http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Endocrinol+Metab+2006%3B+91(5)%3A1802-1810)

40. Haan MN, Klein R, Klein BE, Deng Y, Blythe LK, Seddon JM, et al. Hormone therapy and age-related macular degeneration: the Women's Health Initiative Sight Exam Study. *Arch Ophthalmol* 2006; 124(7):988-992. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Ophthalmol+2006%3B+124\(7\)%3A988-992](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Ophthalmol+2006%3B+124(7)%3A988-992).
41. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. *Arch Intern Med* 2006; 166(9):1027-1032. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2006%3B+166\(9\)%3A1027-1032](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2006%3B+166(9)%3A1027-1032)
42. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. *Arch Intern Med* 2006; 166(3):357-365. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2006%3B+166\(3\)%3A357-365](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2006%3B+166(3)%3A357-365)
43. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. *Circulation* 2006; 113(20):2425-2434. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Circulation+2006%3B+113\(20\)%3A2425-2434](http://www.ncbi.nlm.nih.gov/pubmed/?term=Circulation+2006%3B+113(20)%3A2425-2434).
44. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. *JAMA* 2006; 295(14):1647-1657. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2006%3B+295\(14\)%3A1647-1657](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2006%3B+295(14)%3A1647-1657).
45. Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. *J Bone Miner Res* 2006; 21(6):817-828. [http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Bone+Miner+Res+2006%3B+21\(6\)%3A817-828](http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Bone+Miner+Res+2006%3B+21(6)%3A817-828)
46. Bonds DE, Lasser N, Qi L, Brzyski R, Cann B, Heiss G, et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. *Diabetologia* 2006; 49(3):459-468. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Diabetologia+2006%3B+49\(3\)%3A459-468](http://www.ncbi.nlm.nih.gov/pubmed/?term=Diabetologia+2006%3B+49(3)%3A459-468).
47. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA* 2007; 297(13):1465-1477. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2007%3B+297\(13\)%3A1465-1477](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2007%3B+297(13)%3A1465-1477).
48. Kooperberg C, Cushman M, Hsia J, Robinson J, Aragaki A, Lynch J, et al. Can biomarkers identify women at increased stroke risk? The Women's Health Initiative hormone trials. *PLoS Clin Trials* 2007; 2(6): e28. [http://www.ncbi.nlm.nih.gov/pubmed/?term=PLoS+Clin+Trials+2007%3B+2\(6\)%3A+e28](http://www.ncbi.nlm.nih.gov/pubmed/?term=PLoS+Clin+Trials+2007%3B+2(6)%3A+e28).
49. Jackson RD, Shidham S. The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: Lessons learned from the Women's Health Initiative. *Curr Osteoporos Rep* 2007; 5(4):153-159. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Curr+Osteoporos+Rep+2007%3B+5\(4\)%3A153-159](http://www.ncbi.nlm.nih.gov/pubmed/?term=Curr+Osteoporos+Rep+2007%3B+5(4)%3A153-159).
50. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al. for the WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. *N Engl J Med* 2007; 356(25):2591-2602. [http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2007%3B+356\(25\)%3A2591-2602](http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2007%3B+356(25)%3A2591-2602)
51. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA* 2007; 297(13):1465-1477. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2007%3B+297\(13\)%3A1465-1477](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2007%3B+297(13)%3A1465-1477).
52. Anderson GL, Kooperberg C, Geller N, Rossouw JE, Pettinger M, Prentice RL. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. *Clin Trials* 2007; 4(3):207-217. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Clin+Trials+2007%3B+4\(3\)%3A207-217](http://www.ncbi.nlm.nih.gov/pubmed/?term=Clin+Trials+2007%3B+4(3)%3A207-217)
53. Allison MA, Manson JE, Langer RD, Carr JJ, Rossouw JE, Pettinger MB, et al for the Women's Health Initiative and Women's Health Initiative Coronary Artery Calcium Study Investigators. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. *Menopause* 2008; 15(4 Pt 1):639-647. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2008%3B+15\(4+Pt+1\)%3A639-647](http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2008%3B+15(4+Pt+1)%3A639-647)
54. Hsia J, Otvos JD, Rossouw JE, Wu L, Wassertheil-Smoller S, Hendrix SL, et al. for the Women's Health Initiative Research Group. Lipoprotein particle concentrations may explain the absence of coronary protection in the Women's Health Initiative Hormone Trials. *Arterioscler Thromb Vasc Biol* 2008;

- 28(9):1666-1671.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Arterioscler+Thromb+Vasc+Biol+2008%3B+28\(9\)%3A1666-1671](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arterioscler+Thromb+Vasc+Biol+2008%3B+28(9)%3A1666-1671).
55. Rossouw JE, Cushman M, Greenland P, Lloyd-Jones DM, Bray P, Kooperberg C, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. *Arch Intern Med* 2008; 168(20):2245-2253.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2008%3B+168\(20\)%3A2245-2253](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2008%3B+168(20)%3A2245-2253).
 56. Chen Z, Beck T, Cauley JA, Lewis CE, Lacroix A, Bassford T, et al. Hormone therapy improves femur geometry among ethnically diverse postmenopausal participants in the Women's Health Initiative Hormone Intervention Trials. *J Bone Miner Res* 2008; 23(12):1935-1945.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Bone+Miner+Res+2008%3B+23\(12\)%3A1935-1945](http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Bone+Miner+Res+2008%3B+23(12)%3A1935-1945).
 57. Bray PF, Larson JC, Lacroix AZ, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. *Am J Cardiol* 2008; 101(11):1599-1605.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Cardiol+2008%3B+101\(11\)%3A1599-1605](http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Cardiol+2008%3B+101(11)%3A1599-1605).
 58. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, Hendrix SL, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. *Am J Epidemiol* 2008; 15;167(10):1207-1216.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Epidemiol+2008%3B+15%3B167\(10\)%3A1207-1216](http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Epidemiol+2008%3B+15%3B167(10)%3A1207-1216).
 59. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. *JAMA* 2008; 299(9):1036-1045.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2008%3B+299\(9\)%3A1036-1045](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2008%3B+299(9)%3A1036-1045).
 60. Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. *Cancer Epidemiol Biomarkers Prev* 2008; 17(10):2609-2618.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+Epidemiol+Biomarkers+Prev+2008%3B+17\(10\)%3A2609-2618](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+Epidemiol+Biomarkers+Prev+2008%3B+17(10)%3A2609-2618).
 61. Walitt B, Pettinger M, Weinstein A, et al. Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. *Arthritis Rheum* 2008; 59(3):302-310.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Arthritis+Rheum+2008%3B+59\(3\)%3A302-310](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arthritis+Rheum+2008%3B+59(3)%3A302-310).
 62. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. *JAMA* 2008; 299(9):1036-1045.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2008%3B+299\(9\)%3A1036-1045](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2008%3B+299(9)%3A1036-1045).
 63. Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL. Conjugated equine estrogen and risk of benign proliferative breast disease: A randomized controlled trial. *JNCI* 2008; 100(8):563-571.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2008%3B+100\(8\)%3A563-571](http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2008%3B+100(8)%3A563-571).
 64. Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS, Ginsberg M, Wassertheil-Smoller S, Page DL. Estrogen plus progestin and risk of benign proliferative breast disease. *Cancer Epidemiol Biomarkers Prev* 2008; 17(9):2337-2343.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+Epidemiol+Biomarkers+Prev+2008%3B+17\(9\)%3A2337-2343](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+Epidemiol+Biomarkers+Prev+2008%3B+17(9)%3A2337-2343).
 65. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O'Sullivan MJ, Rossouw JE, Anderson GL. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. *Am J Epidemiol* 2008; 167(12):1407-1415.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Epidemiol+2008%3B+167\(12\)%3A1407-1415](http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Epidemiol+2008%3B+167(12)%3A1407-1415).
 66. Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gillian MA, et al. for the Women's Health Initiative Investigators. Estrogen plus progestin and breast cancer detection by means of mammography

- and breast biopsy. *Arch Intern Med* 2008; 168(4):370-377.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2008%3B+168\(4\)%3A370-377](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2008%3B+168(4)%3A370-377)
67. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. *Lancet* 2009; 374(9697):1243-1251.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Lancet+2009%3B+374\(9697\)%3A1243-1251](http://www.ncbi.nlm.nih.gov/pubmed/?term=Lancet+2009%3B+374(9697)%3A1243-1251)
 68. Prentice RL, Huang Y, Hinds DA, Peters U, Pettinger M, Cox DR, et al. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. *Cancer Epidemiol Biomarkers Prev* 2009; 18(11):3079-3085.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+Epidemiol+Biomarkers+Prev+2009%3B+18\(11\)%3A3079-3085](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+Epidemiol+Biomarkers+Prev+2009%3B+18(11)%3A3079-3085)
 69. Coker LH, Espeland MA, Rapp SR, Legault C, Resnick SM, Hogan P, Gaussoin S, Dailey M, Shumaker SA. Postmenopausal Hormone Therapy and Cognitive Outcomes: the Women's Health Initiative Memory Study (WHIMS). *J Steroid Biochem Mol Biol* 2010; 118(4-5):304-310.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Steroid+Biochem+Mol+Biol+2010%3B+118\(4-5\)%3A304-310](http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Steroid+Biochem+Mol+Biol+2010%3B+118(4-5)%3A304-310)
 70. Pitteri SJ, Hanash SM, Aragaki A, Amon LM, Chen L, Busald Buson T, Paczesny S, Katayama H, Wang H, Johnson MM, Zhang Q, McIntosh M, Wang P, Kooperberg C, Rossouw JE, Jackson R, Manson JE, Hsia J, Liu S, Martin L, Prentice RL. Postmenopausal estrogen and progestin effects on the serum proteome. *Genome Med* 2009; 1(12):121.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Genome+Med+2009%3B+1\(12\)%3A121](http://www.ncbi.nlm.nih.gov/pubmed/?term=Genome+Med+2009%3B+1(12)%3A121)
 71. Crandall CJ, Aragaki AK, Chlebowski RT, McTiernan A, Anderson G, Hendrix SL, Cochrane BB, Kuller LH, Cauley JA. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk. *Arch Intern Med* 2009; 169(18):1684-1691.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2009%3B+169\(18\)%3A1684-1691](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2009%3B+169(18)%3A1684-1691)
 72. Resnick SM, Espeland MA, An Y, Maki PM, Coker LH, Jackson R, Stefanick ML, Wallace R, Rapp SR; for the Women's Health Initiative Study of Cognitive Aging Investigators. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. *J Clin Endocrinol Metab* 2009; 94(11):4152-4161.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Endocrinol+Metab+2009%3B+94\(11\)%3A4152-4161](http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Endocrinol+Metab+2009%3B+94(11)%3A4152-4161)
 73. Resnick SM, Espeland MA, Jaramillo SA, Hirsch C, Stefanick ML, Murray AM, Ockene J, Davatzikos C. Postmenopausal hormone therapy and regional brain volumes: The WHIMS-MRI Study. *Neurology* 2009; 72(2):135-142.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Neurology+2009%3B+72\(2\)%3A135-142](http://www.ncbi.nlm.nih.gov/pubmed/?term=Neurology+2009%3B+72(2)%3A135-142)
 74. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. *Am J Epidemiol.* 2009; 170(1):12-23. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Epidemiol.+2009%3B+170\(1\)%3A12-23](http://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Epidemiol.+2009%3B+170(1)%3A12-23)
 75. Katayama H, Paczesny S, Prentice R, Aragaki A, Faca VM, Pitteri SJ, Zhang Q, Wang H, Silva M, Kennedy J, Rossouw J, Jackson R, Hsia J, Chlebowski R, Manson JE, Hanash SM. Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. *Genome Med* 2009; 1(4):47.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Genome+Med+2009%3B+1\(4\)%3A47](http://www.ncbi.nlm.nih.gov/pubmed/?term=Genome+Med+2009%3B+1(4)%3A47)
 76. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. *N Engl J Med* 2009; 360(6):573-587.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2009%3B+360\(6\)%3A573-587](http://www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med+2009%3B+360(6)%3A573-587)
 77. Prentice RL, Pettinger M, Beresford SA, Wactawski-Wende J, Hubbell FA, et al. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative Clinical Trial and Observational Study. *Cancer Epidemiol Biomarkers Prev* 2009; 18(5):1531-1537.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+Epidemiol+Biomarkers+Prev+2009%3B+18\(5\)%3A1531-1537](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+Epidemiol+Biomarkers+Prev+2009%3B+18(5)%3A1531-1537)

78. McTiernan A, Chlebowski RT, Martin C, Peck JD, Aragaki A, Pisano ED, Wang CY, Johnson KC, Manson JE, Wallace RB, Vitolins MZ, Heiss G. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the Women's Health Initiative Randomized Trial. *J Clin Oncol* 2009; 27(36):6135-6143.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Oncol+2009%3B+27\(36\)%3A6135-6143](http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Oncol+2009%3B+27(36)%3A6135-6143).
79. Espeland MA, Tindle HA, Bushnell CA, Jaramillo SA, Kuller LH, Margolis KL, et al. for the Women's Health Initiative Memory Study. Brain volumes, cognitive impairment, and conjugated equine estrogens. *J Gerontol A Biol Sci Med Sci* 2009; 64(12):1243-1250.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Gerontol+A+Biol+Sci+Med+Sci+2009%3B+64\(12\)%3A1243-1250](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gerontol+A+Biol+Sci+Med+Sci+2009%3B+64(12)%3A1243-1250)
80. Coker LH, Hogan PE, Bryan NR, Kuller LH, Margolis KL, Bettermann K, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: The WHIMS-MRI Study. *Neurology* 2009; 72(2):125-134. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Neurology+2009%3B+72\(2\)%3A125-134](http://www.ncbi.nlm.nih.gov/pubmed/?term=Neurology+2009%3B+72(2)%3A125-134).
81. Edlefsen KL, Jackson RD, Prentice RL, Janssen I, Rajkovic A, O'Sullivan MJ, Anderson G. The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women. *Menopause* 2010; 17(3):622-629.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2010%3B+17\(3\)%3A622-629](http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2010%3B+17(3)%3A622-629)
82. Maalouf NM, Sato AH, Welch BJ, Howard BV, Cochrane BB, Sakhaee K, Robbins JA. Postmenopausal hormone use and the risk of nephrolithiasis: Results from the Women's Health Initiative hormone therapy trials. *Arch Intern Med* 2010; 170(18):1678-1685.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2010%3B+170\(18\)%3A1678-1685](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Intern+Med+2010%3B+170(18)%3A1678-1685)
83. Cauley JA, Lacroix AZ, Robbins JA, Larson J, Wallace R, Wactawski-Wende J, Chen Z, Bauer DC, Cummings SR, Jackson R. Baseline serum estradiol and fracture reduction during treatment with hormone therapy: The Women's Health Initiative randomized trial. *Osteoporos Int* 2010; 21(1):167-177.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Osteoporos+Int+2010%3B+21\(1\)%3A167-177](http://www.ncbi.nlm.nih.gov/pubmed/?term=Osteoporos+Int+2010%3B+21(1)%3A167-177).
84. Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. *Menopause* 2010; 17(5):946-954. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2010%3B+17\(5\)%3A946-954](http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2010%3B+17(5)%3A946-954).
85. Chlebowski RT, Anderson G, Manson JE, Pettinger M, Yasmeen S, Lane D, Langer RD, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. *J Clin Oncol* 2010; 28(16):2690-2697.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Oncol+2010%3B+28\(16\)%3A2690-2697](http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Oncol+2010%3B+28(16)%3A2690-2697)
86. Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, et al. Lung cancer among postmenopausal women treated with estrogen alone in the Women's Health Initiative Randomized Trial. *JNCI* 2010; 102(18):1413-1421.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2010%3B+102\(18\)%3A1413-1421](http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2010%3B+102(18)%3A1413-1421).
87. Michael YL, Gold R, Manson JE, et al. Hormone therapy and physical function change among older women in the Women's Health Initiative: a randomized controlled trial. *Menopause* 2010; 17(2):295-302.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2010%3B+17\(2\)%3A295-302](http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2010%3B+17(2)%3A295-302).
88. Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. *Ann Intern Med* 2010; 16;152(4):211-217.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Ann+Intern+Med+2010%3B+16%3B152\(4\)%3A211-217](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ann+Intern+Med+2010%3B+16%3B152(4)%3A211-217)
89. Espeland ME, Brunner RL, Hogan PE, Rapp SR, Coker LH, Legault C, Granek I, and Resnick SM, for the Women's Health Initiative Study of Cognitive Aging Study Group. Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative Study of Cognitive Aging Extension. *J Am Geriatr Soc* 2010; 58(7):1263-1271.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Am+Geriatr+Soc+2010%3B+58\(7\)%3A1263-1271](http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Am+Geriatr+Soc+2010%3B+58(7)%3A1263-1271)
90. Brunner RL, Aragaki A, Barnabei V, Cochrane BB, Gass M, Hendrix S, et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized,

- placebo-controlled trial. *Menopause* 2010; 17(5):946-954.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2010%3B+17\(5\)%3A946-954](http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2010%3B+17(5)%3A946-954).
91. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. for the WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. *JAMA* 2010; 304(15):1684-92. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2010%3B+304\(15\)%3A1684-92](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2010%3B+304(15)%3A1684-92).
 92. Chlebowski RT, Anderson G, Manson JE, Pettinger M, Yasmeeen S, Lane D, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. *J Clin Onco* 2010; 28(16):2690-2697.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Onco+2010%3B+28\(16\)%3A2690-2697](http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Onco+2010%3B+28(16)%3A2690-2697).
 93. Gass M, Cochrane BB, Larson JC, Manson, JE, Barnabei VM, Brzyski RG, et al. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women's Health Initiative. *Menopause* 2011; 18(11):1160-1171.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=2011%3B+18\(11\)%3A1160-1171](http://www.ncbi.nlm.nih.gov/pubmed/?term=2011%3B+18(11)%3A1160-1171).
 94. Bea JW, Zhao Q, Cauley JA, Lacroix AZ, Bassford T, Lewis CE, et al. Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials. *Menopause* 2011 Jan;18(1):44-52.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2011+Jan%3B18\(1\)%3A44-52](http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2011+Jan%3B18(1)%3A44-52).
 95. Tang JY, Spaulhurst KM, Chlebowski RT, Wactawski-Wende J, Keiser E, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: Women's Health Initiative Randomized Trials. *JNCI* 2011; 103(19): 1469-1475.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2011%3B+103\(19\)%3A+1469-1475](http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2011%3B+103(19)%3A+1469-1475).
 96. Chlebowski RT, Anderson GL. The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. *JNCI* 2011; 103(4):284-285.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2011%3B+103\(4\)%3A284-285](http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2011%3B+103(4)%3A284-285)
 97. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. *JAMA* 2011; 305(13):1305-1314.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2011%3B+305\(13\)%3A1305-1314](http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2011%3B+305(13)%3A1305-1314).
 98. Rossouw J, Bray P, Liu J, Kooperberg C, Hsia J, Lewis C, et al. Estrogen receptor polymorphisms and the vascular effects of hormone therapy. *Arterioscler Thromb Vasc Biol* 2011; 31(2):464-469.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Arterioscler+Thromb+Vasc+Biol+2011%3B+31\(2\)%3A464-469](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arterioscler+Thromb+Vasc+Biol+2011%3B+31(2)%3A464-469).
 99. Rossouw JE, Prentice RL, Manson JE, et al. Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy. *Circulation* 2012; 126(13):1577-1586.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Circulation+2012%3B+126\(13\)%3A1577-1586](http://www.ncbi.nlm.nih.gov/pubmed/?term=Circulation+2012%3B+126(13)%3A1577-1586).
 100. Chlebowski RT, Anderson GL. Changing concepts: Menopausal hormone therapy and breast cancer. *JNCI* 2012; 104(7):517-527. [http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2012%3B+104\(7\)%3A517-527](http://www.ncbi.nlm.nih.gov/pubmed/?term=JNCI+2012%3B+104(7)%3A517-527).
 101. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. *Lancet Oncol* 2012; 13(5):476-486.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Lancet+Oncol+2012%3B+13\(5\)%3A476-486](http://www.ncbi.nlm.nih.gov/pubmed/?term=Lancet+Oncol+2012%3B+13(5)%3A476-486).
 102. Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson G, Chlebowski RT. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. *Breast Cancer Res Treat* 2012; 132(1):275-285.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Breast+Cancer+Res+Treat+2012%3B+132\(1\)%3A275-285](http://www.ncbi.nlm.nih.gov/pubmed/?term=Breast+Cancer+Res+Treat+2012%3B+132(1)%3A275-285).
 103. Simon MS, Chlebowski RT, Wactawski-Wende J, Johnson KC, Muskovitz A, et al. Estrogen plus progestin and colorectal cancer incidence and mortality. *J Clin Oncol* 2012; 30(32):3983-90.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Oncol+2012%3B+30\(32\)%3A3983-90](http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Clin+Oncol+2012%3B+30(32)%3A3983-90).

104. Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson GL, et al. Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. *Breast Cancer Res Treat* 2012; 131(3):969-979.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Breast+Cancer+Res+Treat+2012%3B+131\(3\)%3A969-979](http://www.ncbi.nlm.nih.gov/pubmed/?term=Breast+Cancer+Res+Treat+2012%3B+131(3)%3A969-979).
105. Perez MV, Wang PJ, Larson JC, Virnig BA, Cochrane B, Curb JD, et al. Effects of postmenopausal hormone therapy on incident atrial fibrillation: The Women's Health Initiative Randomized Controlled Trials. *Circ Arrhythm Electrophysiol* 2012; 5(6):1108-1116.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Arrhythm+Electrophysiol+2012%3B+5\(6\)%3A1108-1116](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arrhythm+Electrophysiol+2012%3B+5(6)%3A1108-1116).
106. Mackey RH, Fanelli TJ, Modugno F, Cauley JA, McTigue KM, Brooks MM, et al. Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. *Cancer Epidemiol Biomarkers Prev* 2012; 21(11):2022-2032.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+Epidemiol+Biomarkers+Prev+2012%3B+21\(11\)%3A2022-2032](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cancer+Epidemiol+Biomarkers+Prev+2012%3B+21(11)%3A2022-2032).
107. Huang Y, Ballinger DG, Stokowski R, Beilharz E, Robinson JG, Liu S, et al. Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. *Genome Med* 2012; 4(7):57. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Genome+Med+2012%3B+4\(7\)%3A57](http://www.ncbi.nlm.nih.gov/pubmed/?term=Genome+Med+2012%3B+4(7)%3A57).
108. Rossouw JE, Johnson KC, Pettinger M, Cushman M, Sandset PM, Kuller L, et al. Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy. 2012; 43(4):952-957.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Rossouw+JE%2C+Johnson+KC%2C+Pettinger+M%2C+Cushman+M%2C+Sandset+PM%2C+Kuller+L+2012>
109. Rossouw JE, Prentice RL, Manson JE, Aragaki AK, Hsia J, Martin LW, et al. Relationships of coronary heart disease with 27-hydroxycholesterol, low density lipoprotein cholesterol, and menopausal hormone therapy. *Circulation* 2012; 126(13):1577-1586.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Circulation+2012%3B+126\(13\)%3A1577-1586](http://www.ncbi.nlm.nih.gov/pubmed/?term=Circulation+2012%3B+126(13)%3A1577-1586).
110. Luo J, Cochrane BB, Wactawski-Wende J, Hunt JR, Ockene JK, Margolis KL. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. *Breast Cancer Res Treat* 2013; 137(3):915-925. [http://www.ncbi.nlm.nih.gov/pubmed/?term=Breast+Cancer+Res+Treat+2013%3B+137\(3\)%3A915-925](http://www.ncbi.nlm.nih.gov/pubmed/?term=Breast+Cancer+Res+Treat+2013%3B+137(3)%3A915-925).
111. Canonico M, Plu-Bureau G, O'Sullivan MJ, Stefanick ML, Cochrane B, Scarabin PY, Manson JE. Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative hormone therapy clinical trials. *Menopause* 2013; in press.[e-pub 6/10/13]
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Canonico+M%2C+Plu-Bureau+G%2C+O'Sullivan+MJ%2C+Stefanick+ML%2C+Cochrane+B%2C+Scarabin+PY2013>
112. Espeland MA, Pettinger M, Falkner KL, Shumaker SA, Limacher M, Thomas F, et al. Demographic and health factors associated with enrollment in posttrial studies: The Women's Health Initiative hormone therapy trials. *Clin Trials* 2013; 10(3):463-472.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Clin+Trials+2013%3B+10\(3\)%3A463-472](http://www.ncbi.nlm.nih.gov/pubmed/?term=Clin+Trials+2013%3B+10(3)%3A463-472).
113. Chlebowski RT, Cirillo DJ, Eaton CB, Stefanick ML, Pettinger M, Carbone LD, et al. Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. *Menopause* 2013; 20(6):600-608.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2013%3B+20\(6\)%3A600-608](http://www.ncbi.nlm.nih.gov/pubmed/?term=Menopause+2013%3B+20(6)%3A600-608)
114. Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, Trevisan M, Manson JE. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: A nested case-control study within the Women's Health Initiative randomized clinical trials. *Menopause* 2013; 20(3):254-260
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Wild+RA%2C+Wu+C%2C+Curb+JD%2C+Martin+LW%2C+Phillips+L%2C+Stefanick+M%2C+Trevisan+2013>.
115. Robbins JA, Aragaki A, Crandall CJ, Manson JE, Carbone L, Jackson R, et al. Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy. *Menopause* 2013; [e-pub 6/24/13]

<http://www.ncbi.nlm.nih.gov/pubmed/?term=Robbins+JA%2C+Aragaki+A%2C+Crandall+CJ%2C+Manson+JE%2C+Carbone+L%2C+Jackson+R+2013>.

116. Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, Leblanc ES, et al. for the WHIMSY Study Group. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50-55 years. JAMA Intern Med 2013; [e-pub 6/24/13]

<http://www.ncbi.nlm.nih.gov/pubmed/?term=Espeland+MA%2C+Shumaker+SA%2C+Leng+I%2C+Manson+JE%2C+Brown+CM%2C+Leblanc+ES+2013>.

Additional publications have been developed from the publically available WHI dataset. Such manuscripts, which do not undergo review by the WHI Publications & Presentations Committee, may not reflect the views and data interpretation of the WHI research team, have not been included in the above listing.